Evogene (EVGN) Q3 2026 Earnings Call Transcript
Bayer agreement expiry and warrant costs weighed on results as new AI-designed candidates advanced.
Evogene (EVGN) reported a decline in revenue for the third quarter and first nine months of 2026, largely due to the end of a significant partnership and reduced sales from a subsidiary. Management highlighted the company's focus on creating unique small-molecule assets using its AI technology, ChemPass AI, for pharmaceutical and agricultural uses.
The financial results were influenced by transaction costs from warrant inducements and one-time legal fees. Evogene now holds a cash reserve of $9.2 million and has cut operating expenses in various subsidiaries. Host: Welcome to Evogene's Third Quarter 2026 Results Conference Call. Reminder, this call is being recorded on November 19, 2026.
Let's caution you that some statements made during this earnings call are forward-looking and may not necessarily come to pass. We'll now hear from Ofer Haviv. Mr. Haviv, please proceed. Ofer Haviv: Good morning, everyone, and thank you for tuning in to Evogene's Q3 2026 Analyst Call. Your continued interest in the company is greatly appreciated.
Today, we'll focus on two of our internal development programs that showcase our strategy of using our AI-driven platform, ChemPass AI, to develop proprietary assets with substantial commercial potential. Our first program targets acute graft-versus-host disease (aGVHD), while the second involves the AgPlenus fungicide discovery program targeting Septoria.
Both initiatives aim to create solutions with novel biological mechanisms of action. These programs not only hold significant economic value but also demonstrate the strength of our ChemPass AI platform. I'll now hand the call over to Polina Ravzin, our VP Finance, for a detailed financial analysis.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.